Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
August 31, 2020 16:10 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response
August 13, 2020 08:00 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...
Dynavax Announces Second Quarter 2020 Financial Results
August 06, 2020 16:02 ET
|
Dynavax Technologies Corporation
Second quarter 2020 HEPLISAV-B® net product revenue of $2.4 millionMultiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications, including...
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales
August 03, 2020 08:00 ET
|
Dynavax Technologies Corporation
SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotideTriSalus plans to further develop SD-101 as an oncology therapeutic ...
Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
July 30, 2020 16:05 ET
|
Dynavax Technologies Corporation
EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will...
Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
July 23, 2020 08:00 ET
|
Dynavax Technologies Corporation
Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018In preclinical testing, the combination generated strong virus...
Dynavax Announces the Appointment of Two New Board Members
July 21, 2020 16:10 ET
|
Dynavax Technologies Corporation
Ms. Julie Eastland, a strategic and financial executive with over 25 years of experience in biotechnology companiesMr. Brent MacGregor, a senior executive with over 20 years of global strategy and...
Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
July 16, 2020 08:40 ET
|
Dynavax Technologies Corporation
Development funded under contract award from NIAID/NIH as part of the CIVICs programCurrently no approved universal influenza vaccineCDC estimates 35.5 million people were infected with influenza in...
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant
July 14, 2020 08:00 ET
|
Dynavax Technologies Corporation
Medicago expects to enroll 180 healthy adult participantsPreliminary safety and immunogenicity results are expected in October 2020Dynavax is providing CpG 1018, the adjuvant contained in its U.S....
Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes
July 10, 2020 16:01 ET
|
Dynavax Technologies Corporation
- People with diabetes are two times more likely to become infected with the hepatitis B virus (HBV) and up to four times as likely to get HBV-related liver cancer - Hawaii has one of the highest...